SCHEMBL2644593

SCHEMBL2644593

CCCc1noc(COc2cc(C(=O)O)cc3c2CC(C)(C)O3)n1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.32
HSD17B10 Q99714 4/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
ALOX15 P16050 1/20 0.32
APOBEC3A P31941 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
ALDH1A1 P00352 4/20 0.32
HPGD P15428 4/20 0.32
GAA P10253 3/20 0.32
GLA P06280 2/20 0.32
CASP1 P29466 2/20 0.32
CASP7 P55210 1/20 0.32
FFAR1 O14842 4/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 2/20 0.31
TP53 P04637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
GCK P35557 1/20 0.31
HTT P42858 1/20 0.31
CHRM2 P08172 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2643969 0.86 GSTP1 (0.41) KDM4EHSD17B10L3MBTL1ALDH1A1HPGD
SCHEMBL2645105 0.82 SMPD1 (0.35) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL2643790 0.80 NPC1 (0.50) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL2644888 0.80 GCGR (0.36) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL2643933 0.78 TSHR (0.43) KDM4EHSD17B10ALOX15ALDH1A1HPGD
SCHEMBL2645442 0.76 PIK3CA (0.33) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL643590 0.75 MAOB (0.49) HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL2645457 0.73 KDM4A (0.37) KDM4EHSD17B10L3MBTL1ALDH1A1HPGD
SCHEMBL2644213 0.71 IRAK4 (0.39) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL2643648 0.71 KDM5A (0.41) KDM4EHSD17B10L3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 KDM4E 1790/4885HSD17B10 1912/4885L3MBTL1 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.